IMOU
Imou, a leading smart IoT solution and service provider, is pleased to unveil three new smart security cameras in European market at Amazon’s Prime Day Launch event 2019, as the only supplier in the surveillance camera category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190711005425/en/
With a “3-in-1” business system encompassing Imou Cloud, smart devices and intelligent algorithms, Imou is committed to bringing customers peace of mind. It has deployed AWS-based servers in 14 countries, including Germany, Ireland and the United States, to offer users bank-level encrypted and GDPR-compiled cloud storage services, putting users’ privacy as top priority.
The three new arrivals not only are enhanced with AI technology to avoid false alerts, but also support 1080P high definition, with clear night vision, and H.265 compression. Besides, the Imou range is compatible with Amazon Alexa, Google Assistant and IFTTT, redefining the standard for Smart Home Security Camera in the IoT era.
Ranger 2
Ranger 2 can pan and tilt for a 360° coverage and protection, both day and night. With AI human detection, Ranger 2 can identify human beings whilst ignoring pets, insets or other moving objects to only alert you when you have a genuine detection to avoid countless false alerts. Whenever it detects human motion, Ranger 2 will send an immediate alert, and the built-in siren will deter intruders; at the same time, the camera will automatically track and record everything, featuring smart tracking. An abnormal sound such as a baby crying will also trigger Ranger 2 to send an immediate alert to the phone. In addition, you can easily turn off the camera lens via Imou app, to protect your privacy while at home.
Cue 2
Cue 2, slim but extremely smart, shares every feature with Ranger 2 and distinguishes itself in the design. The magnetic mount makes it easy to install on any magnetic surface. With a 131° super wide viewing angle, it’s particularly suitable for monitoring pets and babies.
Bullet Lite
Bullet Lite, offering 1080P (2 Megapixel) and 4 Megapixel versions, is an IP67 weatherproof security camera designed for outdoor environments. The built-in microphone picks up sounds clearly while monitoring. Videos can be easily stored and accessed on SD card, NVR or Cloud. Bullet Lite is equipped with a high-quality sensor and IR lights, rendering clear imaging at night even from 30m/98ft away. It sends instant alerts to the phone whenever it detects motion, keeping you aware of what's going on around home from anywhere.
With the debut of the 3 smart security cameras at Amazon’s Prime Day Launch event, Imou is making a strong presence in the European market, with plans to produce more high-quality products ranging from security cameras to other smart IoT products including video doorbells, security alarm system, and much more. Imou also provides professional and localised after-sale services supported by technical support team in Europe.
Official website: www.imoulife.com/
Exclusive Deal for Amazon Prime Members: www.imoulife.com/activity/primeDay
View source version on businesswire.com: https://www.businesswire.com/news/home/20190711005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom